Evidence map›Paper›PMID 29937430›Full record

Trial reportDiabetes care2018

Sotagliflozin in Combination With Optimized Insulin Therapy in Adults With Type 1 Diabetes: The North American inTandem1 Study.

John B Buse, Satish K Garg, Julio Rosenstock, Timothy S Bailey, Phillip Banks, Bruce W Bode, Thomas Danne, Jake A Kushner, Wendy S Lane, Pablo Lapuerta and 5 more

Registry-linked trialAbstract readClinical Trial, Phase IIIMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Diabetes care, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07325201 (Mitigating Diabetic Ketoacidosis in People With T1D and Chronic Kidney Disease on an SGLT1&2 Inhibitor), which is not on this map. Cited by 112 papers, 20 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
112citing papers in PubMed, 20 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07325201 phase2not yet recruitingnot on this mapstarted 2026, after this paper: background citation

Mitigating Diabetic Ketoacidosis in People With T1D and Chronic Kidney Disease on an SGLT1&2 Inhibitor: Ketosis Risk Factor Determination and Incorporation Into an Enhanced Glucose Ketone Report

TypeinterventionalSponsorHealthPartners InstituteRan2026 to 2030Enrolled80ConditionsType 1 Diabetes Mellitus, Chronic Kidney Disease (CKD) With Diabetes Mellitus (DM), Chronic Kidney Disease, Diabetic KetoacidosisArmsSotagliflozin initiation
3 · Its place in the literature

Who cites it

112 citing papers in PubMed, 20 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Guideline
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. Pooled it
  14. Pooled it
  15. Pooled it
  16. Pooled it
  17. Pooled it
  18. Pooled it
  19. Pooled it
  20. Pooled it

52 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

John B BuseDepartment of Medicine, University of North Carolina School of Medicine, Chapel Hill, NC jbuse@med.unc.edu.ORCID 0000-0002-9723-3876
Satish K GargDepartments of Medicine and Pediatrics, Barbara Davis Center for Diabetes, University of Colorado Denver, Aurora, CO.
Julio RosenstockDallas Diabetes Research Center at Medical City, Dallas, TX.ORCID 0000-0001-8324-3275
Timothy S BaileyAMCR Institute, Escondido, CA.
Phillip BanksLexicon Pharmaceuticals, Inc., The Woodlands, TX.
Bruce W BodeAtlanta Diabetes Associates, Emory University School of Medicine, Atlanta, GA.ORCID 0000-0002-9998-055X
Thomas DanneDepartment of Diabetes, Endocrinology, and Clinical Research, Children's and Youth Hospital Auf der Bult, Hannover Medical School, Hannover, Germany.ORCID 0000-0003-0773-6961
Jake A KushnerMcNair Medical Institute and Department of Pediatrics, Baylor College of Medicine and Texas Children's Hospital, Houston, TX.ORCID 0000-0002-3646-1744
Wendy S LaneMountain Diabetes and Endocrine Center, Asheville, NC.
Pablo LapuertaLexicon Pharmaceuticals, Inc., The Woodlands, TX.
Darren K McGuireDepartment of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX.
Anne L PetersKeck School of Medicine of the University of Southern California, Los Angeles, CA.
John ReedEndocrine Research Solutions, Inc., Roswell, GA.
Sangeeta SawhneyLexicon Pharmaceuticals, Inc., The Woodlands, TX.
Paul StrumphLexicon Pharmaceuticals, Inc., The Woodlands, TX.

Funding

Re-Entry Supplement: Investigation of Oral Microbial Enzymes for the Detection and Treatment of Periodontal DiseaseUL1TR002489 · NCATS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI BUSE, JOHN BERNARD, SHAHEEN, NICHOLAS J · 2018 to 2022
$48.6M
North Carolina Translational & Clinical Sciences Institute (NC TraCS)UL1TR001111 · NCATS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI BUSE, JOHN BERNARD, CAREY, TIMOTHY S · 2013 to 2017
$43.9M
NCATS NIH HHS UL1 TR001111NCATS NIH HHS UL1 TR002489
6 · The paper itself

Abstract

objectiveEvaluate the efficacy and safety of the dual sodium-glucose cotransporter 1 (SGLT1) and SGLT2 inhibitor sotagliflozin in combination with optimized insulin in type 1 diabetes (T1D). RESEARCH DESIGN AND

methodsThe inTandem1 trial, a double-blind, 52-week phase 3 trial, randomized North American adults with T1D to placebo (

resultsFrom a mean baseline of 7.57%, placebo-adjusted HbA

conclusionsIn a 1-year T1D study, sotagliflozin combined with optimized insulin therapy was associated with sustained HbA

Indexed as

AdultAgedBody WeightDiabetes Mellitus, Type 1Diabetic KetoacidosisDouble-Blind MethodDrug Therapy, CombinationFemaleGlycated HemoglobinGlycosidesHumansHypoglycemiaInsulinInsulin Infusion SystemsMaleMiddle Aged(2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(methylthio)tetrahydro-2H-pyran-3,4,5-triolGlycated HemoglobinGlycosidesInsulin

Identifiers

PMID29937430
PMCPMC6105319

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.